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ABSTRACT
Introduction: The carbohydrate ‘fuel’ metabolism in a
pregnant woman may have a long-term impact on the
development of her offspring (‘fuel-mediated
teratogenesis’ hypothesis) including in utero exposure
to maternal hyperglycaemia leading to fetal
hyperinsulinaemia, and the consequent increase in fetal
fat cells. Therefore, a feed-forward loop can exist of
rising adiposity and hyperinsulinaemia throughout
childhood, perhaps leading to obesity and diabetes in
later life. There is a need for prospective examination
of body fat distribution in children born to mothers
with different glycaemic levels to understand the
plausible association between glucose metabolism and
future risk of diabetes in offspring. The hypothesis is
that maternal glucose levels in pregnant women are
related to skinfold thickness in their infants.
Methods and analysis: Hyperglycaemia in
pregnancy and adiposity in infants is a multicentre
cohort study to evaluate the effects of glucose levels in
pregnancy on the risk of adverse infant outcomes,
especially in predicting the risk of chronic diseases in
infants. The study aims to recruit 1045 participants
over a period of 1 year, who will be followed up
irrespective of their glycaemia status for a period of
15 months, beginning in the 24th week of gestation.
The glucose levels in pregnant women would be
obtained through oral glucose tolerance testing. The
primary outcome of our study was skinfold thickness
in infants at the age of 6 weeks, 3rd and 9th month
(as a proxy for fat distribution/adiposity).
Ethics and dissemination: The institutional review
board at The Indian Institute of Public Health (IIPH)-
Hyderabad, Public Health Foundation of India has
approved the protocol. All participants are required to
provide written informed consent.
INTRODUCTION
India is dubiously termed as ‘the diabetes
capital of the world’.1 The number of people
with diabetes in India was estimated at 50.8
million in the year 2000 and is projected to
be 70 million by the year 2025.2
Urbanisation-related lifestyle changes are
clearly driving the current epidemics of
obesity and diabetes in the developed and
developing world alike,1 3 but they fail to
explain adequately the remarkable rate and
magnitude of these epidemics.4 Accordingly,
additional contributory mechanisms have
been proposed. The ‘thrifty phenotype’
hypothesis suggests that the risks of obesity,
diabetes and cardiovascular diseases are ‘pro-
grammed’ in early life through the persist-
ence of endocrine, physiological and
metabolic adaptations made in the face of
undernutrition.4 5 The ‘thrifty phenotype’ is
disingenuous, in the sense that it confers an
early survival advantage on the individual
during undernutrition but can become dele-
terious under conditions of overnutrition in
adulthood. Similarly, conservatory adapta-
tions in the genotype of populations that
have undergone rapid transition from epi-
sodic undernutrition to plentiful food supply
results in alterations of genotype, referred to
as the ‘Thrifty Genotype’ hypothesis. One
such is the ‘thrifty (fetal) insulin hypothesis’,
which proposes that low birthweight and type
2 diabetes mellitus (T2DM) are two pheno-
types of the same genotype that also predicts
insulin resistance.6 The ‘thrifty phenotype’
hypothesis is supported by a substantial body
of research in animal models, and by obser-
vational studies.7
It is therefore intriguing to understand the
mechanism that led to T2DM in populations.
Evidence for the relationship between hyper-
glycaemia and adverse effects is stronger when
studied between mothers and offspring (com-
pared with fathers and offspring).7 8
Furthermore, the pattern of birthweight dia-
betes association in high-risk populations, as
shown in the pregnancy cohort from Mysore
in south India,9–11 is often ‘U’ shaped. In this
study, the excess prevalence of diabetes in the
high birthweight group disappeared on adjust-
ing for maternal diabetes, implying a maternal
contribution to the link.12–17 It is therefore
important to explore the persistence and
sequelae of hyperglycaemia in pregnancy into
T2DM in later life.18 The estimates of
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hyperglycaemia among pregnant women in India vary
between 1.5% and 17.7%.3 19 20 This wide variation may
be due to the application of several screening tests of
varied quality and a lack of consensus practice of diagnos-
tic criteria for hyperglycaemia in pregnancy. Part of the
variability may also reﬂect differences in the distribution of
genetic and environmental risk factors. Maternal obesity is
a major and modiﬁable risk factor for hyperglycaemia in
pregnancy,21 22 although there are other non-modiﬁable
factors such as genetic predisposition, age and ethnicity.23
The risks of overt hyperglycaemia in pregnant women to
the health of the mother (greater risk of diabetes in later
life)24 and to the offspring in the short term (adverse peri-
natal outcomes such as macrosomia, birth trauma and
metabolic abnormalities) are well established.25–28 The
probable consequences of hyperglycaemia in pregnant
women can include changes in the intrauterine environ-
ment that might increase childhood obesity risk and
further risk of T2DM.29 Literature reviews indicate that off-
spring of mothers with hyperglycaemia in pregnancy are
at higher risk of obesity,29 30 which may depend on the
form and severity of maternal diabetes.29 31–34 Despite this
evidence, the risks associated with relatively less severe
degrees of glucose intolerance during pregnancy are
unclear. It is found that increasing maternal carbohydrate
intolerance even in normal pregnant women can be asso-
ciated with a graded increase in adverse maternal–fetal
outcomes.8 22
This continuum of slowly increasing risks correspond-
ing to mounting blood glucose levels makes it onerous
to make a distinction between an adverse effect of hyper-
glycaemia and its counterfactual physiological effect.35
Some part of this intricacy is solved by the possibility
that carbohydrate ‘fuel’ metabolism in a pregnant
woman may have a long-term impact on the develop-
ment of her offspring (‘fuel-mediated teratogenesis’
hypothesis).26 This hypothesis proposes that in utero
exposure to maternal hyperglycaemia is thought to
result in fetal hyperinsulinaemia,36 37 and the conse-
quent increase in fetal fat cells. Therefore, this results in
a feed-forward loop of rising adiposity and hyperinsuli-
naemia throughout childhood, perhaps leading to
obesity and diabetes in later life.36 37 The rise in the
prevalence of adiposity and glucose intolerance is
accompanied by a progressive lowering of the age at
onset of these conditions. When this reaches a stage of
substantial overlap with childbearing age among women,
it triggers contributions to the epidemic from ‘fuel-
mediated teratogenesis’. It is thought that the feed
forward mechanism results in transgenerational transmis-
sion of adiposity and glucose intolerance in women.38 If
the propositions incorporating the known hypotheses
are true (see online supplementary ﬁle), there is opti-
mism for a clear strategy for the control of the obesity–
diabetes epidemic through rigorous screening and
management of adiposity and glucose intolerance in
pregnancy.
Rationale
To broaden the plausible association between glucose
metabolism and future risk of diabetes in offspring,
there is a need for prospective examination of body fat
distribution in children born to mothers with different
glycaemic levels.29 39 The hypothesis is that maternal
glucose levels measured by glucose levels in pregnant
women are related to skinfold thickness in their infants.
METHODS
Hyperglycaemia in pregnancy and adiposity in infants
(HyPA) is a multicentre study to evaluate the effects of
glucose levels in pregnancy on the risk of adverse infant
outcomes, especially in predicting the risk of chronic
diseases in infants. HyPA will apply prospective cohort
study design to investigate the extent to which differing
levels of glucose are associated with infant outcomes.
HyPA will provide information to assist clinicians and
policymakers in shaping guidelines for the management
of pregnant women with differing levels of blood
glucose.
Setting
The ﬁeld centres comprise public health facilities in the
city of Bengaluru. Each of these facilities registers
approximately 130–150 pregnant women for antenatal
care every month. A majority of these pregnant women
register for antenatal check-up (ANC) around the 16th
week of pregnancy.40 Generally, a minimum of three
ANCs is offered for the pregnant women and at least
once a month in case of high-risk pregnancies. Located
in a metropolitan city, these hospitals conduct some
laboratory tests on a routine basis.
Sample size: we used STATA/SE V.10.1 for Macintosh
(2008) to calculate the sample size for the HyPA study.41
The study is powered at 90% with α=0.05, β1 coefﬁ-
cient=0.09 and SD=0.5. The current study is planned as
a precursor for a larger cohort study with an estimated
10 000 people. To test the feasibility of the large cohort,
the HyPA study plans to recruit 1000 pregnant women.
The power calculation reveals that for a two-sided 95%
CI, normal approximation yields a power of 32 with
α=0.05, β1 coefﬁcient=0.09 and SD=0.5. The sample size
for the planned large cohort study was calculated by
normal approximation with continuity correction and
the power was 90%. For the current pilot study, we took
10% of the total sample size required for the large study
with a power of 32%.42–47
Study population
The source population for the study will comprise all
pregnant women approaching the study centres for
ANC. The study will be carried out in three selected
health centres in Bengaluru city. We aim to recruit
around 350–375 pregnant women in each centre over
the next year resulting in the desired sample size. The
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participation in the study is voluntary and the partici-
pants will be instructed regarding the steps in the study,
including the adverse effects. The recruitment will be
carried out based on the standard protocol and after
obtaining informed consent from the pregnant women.
The cohort study aims to recruit 1045 participants over a
period of 1 year, who will be followed up irrespective of
their glycaemia status for a period of 15 months, begin-
ning in the 24th week of gestation. Adiposity levels in
the offspring will be compared based on the glycaemic
status of the mother.
Participants: The women will be recruited at or before
24 weeks of gestation. They will be recruited for the
study after obtaining informed consent and relevant
details will be noted on a predesigned data collection
format.
The eligibility criteria are as follows:
The age of the woman should be ≥18 years and
≤40 years and gestational age should be ≥14 weeks and
≤24 weeks. The HIV test result should be negative
and the woman should be accessible to the study team
for the next 1 year, so she should agree to reside in the
study area for at least a year.
The exclusion criteria are:
▸ Hypertension;
▸ Known diabetes;
▸ Heart disease;
▸ Any cancer or renal disease.
▸ In addition, conditions like:
– Thyroid diseases, tuberculosis
– Asthma
– Epilepsy
– Current/previous treatment for infertility will be
excluded.
▸ Further, multiple (twin) intrauterine gestation or a
history of four or more live births previously will also
be a criterion for exclusion.
Age and education level will also be recorded for
women who decline to participate. As per our protocol,
all patients will undergo oral glucose tolerance testing
(OGTT) at or after 24–28 weeks of gestation.
Additionally, a glycated haemoglobin (HbA1c) test and
cord blood specimens for insulin will be estimated in a
subset of 300 pregnant women to compare the relative
accuracy of all glucose estimations. In addition, birth-
weight and length of the baby will be measured at birth.
The measurements on skinfold thickness and weight for
length in infants will be recorded at 14 weeks and at 9–
12 months of age.
Consent procedures
All eligible women will be provided study information
leaﬂets. They will be provided time to ensure that they
understand the information and have the opportunity to
clarify and ask questions. All eligible women will have
the choice to participate or decline to participate in the
study. Participants will be assured that their participation
or non-participation in the study will not affect their
clinical care. Written informed consent will be obtained
from the women who wish to participate.
DATA COLLECTION
Baseline
At the time of recruitment to the study, the following
baseline information will be recorded:
▸ Demographic factors
▸ Nutritional assessment
▸ Demographic and social characteristics
▸ Nutritional assessment and dietary characteristics
▸ Physical activity assessment
▸ Social Support Assessment Scale
▸ Mental health assessment
▸ History of tobacco and alcohol intake
▸ Medical and obstetric history
▸ Skinfold thickness in pregnant women
Follow-up
At the time of follow-up during the study, the following
information will be recorded:
▸ Skinfold thickness in infants
▸ Nutritional assessment
▸ Delivery information and infant birth details
▸ Maternal anthropometry
▸ Newborn assessment details
▸ Infant anthropometry at 6 weeks, 3rd and 9th month
▸ Infant morbidity details
▸ Immunisation record
▸ Infant feeding details.
Qualitative analysis
A purposive sample of 20 women will be invited to
attend a semistructured interview to obtain a more
detailed insight of their experiences. We will choose
women of different age groups, social background and
culture, with the aim of capturing information from a
diverse population of women who attend the antenatal
services at public health facilities.
MEASURES
Exposure assessment
The exposure of interest is a continuous range of
glucose. We will follow the recommendations of the
International Association of Diabetes and Pregnancy
Study Groups (IADPSG).48 We will follow the WHO
(1998) recommendations for OGTT, where respondents
are instructed to not have any food after 21:00 on the
day prior to the testing. All respondents who have con-
sented to be tested will be asked to be available at the
study centre by 9:00 and ensured that they have fasted
for a minimum of 10–12 h. After collecting a fasting
sample, 75 mg of anhydrous glucose will be adminis-
tered orally, with 250–300 mL of water, within 5 min of
collecting the sample. All respondents who have con-
sented to be tested will be asked to be available at the
study.
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We will also perform HbA1C in a small subsample of
100 pregnant women to compare with the values
obtained by OGTT. All the samples will undergo exter-
nal quality control check carried out by UK NEQAS for
assuring global quality control. As an important medi-
ator as explained (see ﬁgure 1), cord-blood specimens
will be collected in a small subset at delivery for the
measurement of serum C-peptide and plasma glucose
levels.49 It has been documented that the cord-blood
serum C-peptide level provides a better index of fetal
β-cell function than does the insulin level.49 The reliabil-
ity and validity scores will guide us in determining the
most economical and efﬁcient measure of maternal
glucose levels for the larger cohort study.49
Outcome assessment
The primary outcome of our study is skinfold thickness
in infants at the age of 6 weeks, 3rd and 9th month (as
a proxy for fat distribution/adiposity). Triceps, subscapu-
lar and triceps plus subscapular skinfolds will be mea-
sured. Height will be measured to the last 0.1 cm by
standard methods. Weight will be recorded to the last
100 g. Triceps and subscapular thickness will be mea-
sured as described by Tanner and Whitehouse.50 The
measurements will be carried out using Holtain calipers
(Holtain, UK).51 The triceps skinfold will be measured
over the posterior belly of the triceps muscle of the right
arm, halfway between the acromion and the olecranon,
on a line passing upwards from the olecranon in the
axis of the limb, with the arm extended. Subscapular
skinfold thickness will be measured immediately below
the angle of the right scapula, in the natural cleavage
line of the skin, with the arm held by the side of the
body. Skinfold measurements will be performed by
lifting the full thickness skin with the thumb and index
ﬁnger, with care being taken to exclude any underlying
tissue.52 We will use the sum of four-skinfold thickness to
record measurements. All the research staff have been
trained by experts and will be evaluated with the
support of collaborators from St Johns Hospital and
Research Institute, Bangalore. We will also explore to
study weight for length and waist girth in centimetres as
coprimary outcomes.
Assessment of other covariates
We want to conﬁrm whether these parameters are useful
in the Indian population. We will obtain information on
potential confounders, namely lifestyle factors, age, body
mass index (BMI), family history of diabetes, gestational
age, parity, medical history, family history of hyperten-
sion and socioeconomic status.
Conduct of study and administration of questionnaire
We plan to use a well-structured interviewer-administered
questionnaire for the survey. At ﬁrst instance, the ques-
tionnaire will contain informed consent to participate in
the initial screening programme. If the participant
agrees to take part, then the questions are followed up
further. Extensive literature review and pilot testing will
be carried out to develop and design the ﬁnal format of
the questionnaire. We will collect details about:
▸ Demographic and social characteristics such as age,
religion, caste, marital status, profession, education
and socioeconomic status.
▸ We will also collect information on lifestyle-related
factors such as dietary intake.
▸ Physical activity.
▸ Tobacco use.
▸ Medical history.
We will collect details of high-risk pregnant women
who are positive for any one or more of these traditional
risk factors, namely
▸ Age ≥25 years;
▸ BMI ≥25 kg/m2;
▸ Family history of diabetes mellitus;
▸ Any history of stillbirth;
▸ Gestational diabetes mellitus;
▸ Gross-congenital anomaly;
▸ Macrosomia.
All these variables will be used as effect measure modi-
ﬁers (ﬁgure 1).
Field staff and data collection
A team of trained research assistants will administer the
questionnaire and facilitate implementation of the
research protocol. They will be health professionals who
are trained in taking blood samples, measuring skinfold
thickness and taking height and weight measurements.
Figure 1 Directional acyclic
graph depicting the hypothesis of
hyperglycaemia in pregnancy and
adiposity in infants.
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The team will be stationed in the hospital and would
facilitate implementation of the protocol under the
supervision of the research associate. During their visit to
the hospital, pregnant women will be administered the
questionnaire and the team will collect blood specimens
as per protocol at the 24–28th week. The team will collect
the samples of children and the skinfold measurements
will be measured when the children are brought to the
paediatric outpatient department (OPD) for immunisa-
tion. The schedule of immunisation is at birth, 6, 10 and
14 weeks of age (2.5–3 months). The ﬁrst follow-up meas-
urement will be made when the children are brought to
the OPD at 14 weeks of age for the third dose of polio
and diphtheria, pertussis and tetanus. For children who
miss this visit, the health workers will visit their house to
complete the follow-up examination and collect blood
samples within a month of the missing visit. The parents
would be informed that the second follow-up is sched-
uled at 6 months of age, at the hospital, and that they
should bring the children to the hospital again at that
time. Through this, we will also be testing the feasibility
of collecting blood samples from children for glucose,
insulin and others (see ﬁgure 2).
Plan for bias minimisation and analysis
Adequate power is essential in a cohort study and we
have powered our study based on conservative estimates
of sustained and clinically meaningful differences in
clinical outcome. The participation of volunteers might
indicate that they are more willing to self-select.
However, this will be minimised, as we will select geo-
graphically and socioeconomically diverse health centres
in the city of Bangalore.
In order to control for potential confounding of the
association between covariates and hyperglycaemia, we
will examine a large number of variables simultaneously.
For this purpose, multivariate regression analysis will be
used. Variable selection will be based primarily on prior
knowledge and also the outcome of crude analysis.
Variables with a p value >0.20 in the univariate analysis
will be included in the multivariate analysis. Possible
interactions will also be explored by including product
terms in the model. Multivariate logistic regression ana-
lysis will be applied for calculation of risk for various
maternal risk factors.
At the initial screening during analysis, a summary
measure will be obtained by computing the weighted
average of the ratios, where the weights are the inverses
of the variances of the stratum-speciﬁc prevalence ratios.
An approximation of the variance of a prevalence differ-
ence as described in the standard literature will be used
to calculate the summary prevalence difference based
on the formulae described. We will look at the variables
associated with the presence of risk factors. Crude ratios
(unadjusted), p value and 95% CI will be calculated to
evaluate possible associations between covariates and
outcome variables.
Loss to follow-up may bias the study if it is related to
the outcome of our study. We plan to control this
through our analysis, by collecting some information
from the centres and people are who might potentially
be lost to follow-up. Also, measurement error is unlikely
due to the rigorous standardised measures of exposure
(hyperglycaemia) and outcome (adiposity measured by
Holtain’s calipers). There is no scope for differential
misclassiﬁcation of the outcome, as the research assis-
tants who measure adiposity do not have access to the
results of the exposure. Hence, any misclassiﬁcation of
the outcome will only be non-differential. Centralised
training, quality checks and use of standard equipments
will minimise the misclassiﬁcation, despite being
non-differential.
Figure 2 Flow chart depicting
the steps in the protocol.
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Plan for statistical analysis
We will calculate indicators addressing logistical feasibility
and the process of recruitment in public health facilities in
India. We will also calculate the risk of diabetes in children
at birth, 3 and 6 months of follow-up as a result of hyper-
glycaemia in the mother. We will compare the adiposity
levels up in infants and their association with maternal gly-
caemic levels. At the initial screening, a summary measure
will be obtained by computing the weighted average of the
ratios, where the weights are the inverses of the variances
of the stratum-speciﬁc prevalence ratios. An approxima-
tion of the variance of a prevalence difference as
described in the standard literature will be used to calcu-
late the summary prevalence difference based on the for-
mulae described.53 We will look at the variables associated
with the presence of risk factors. Crude prevalence, OR, p
value and 95% CI will be calculated to evaluate possible
associations between covariates and outcome variables.
In order to control for potential confounding of the
association between covariates and hyperglycaemia, we
will examine a large number of variables simultaneously.
For this purpose, multivariate regression analysis will be
used. Variable selection will be based primarily on prior
knowledge and also the outcome of crude analysis.
Variables with a p value >0.20 in the univariate analysis
will be included in the multivariate analysis. Possible
interactions will also be explored by including product
terms in the model.53 All parameters will be analysed for
statistical signiﬁcance by using Pearson’s χ2 test and the
analysis of variance test. Multivariate logistic regression
analysis will be applied for calculation of risk for various
maternal risk factors. A p value less than 0.05 will be
considered as statistically signiﬁcant. For analytical pur-
poses, patients will be grouped according to glucose
levels and OGTT values and high-risk characteristics.
Ethical considerations
All participants are required to provide written informed
consent (see online supplementary appendix).
DISCUSSION
In summary, previous studies in selected populations
suggest that hyperglycaemia in pregnancy may be an
important risk factor for obesity and type 2 diabetes in
their offspring. Whether the same effects are seen in
Indian populations and at degrees of glycaemia which
are less severe than hyperglycaemia is not known. On the
basis of the model proposed in the protocol here, this
knowledge may be extremely important for developing
an effective strategy for the control of the obesity-
hyperglycaemia epidemic in low-income and middle-
income countries. The results from our study can provide
insights into the relation of adiposity during infancy and
childhood into adult adiposity and T2DM.54
Considerable evidence has emerged from the ‘Mysore
Parthenon Study’,55 56 including the background on
the hypothesis, U-shaped birthweight diabetes associ-
ation57–60 and higher insulin resistance in adipose chil-
dren.59 There is considerable evidence on the effect of
gestational diabetes mellitus and hyperglycaemia during
pregnancy.30 61–65 The current public health scenario in
India is marked by limited accomplishments and persisting
major public health problems.66 Pilot studies such as ours
will pave the way for planning large cohort studies and
provide credible information for evidence-based public
health planning and decision-making in India.67 We aim
to study the feasibility of conducting a large cohort study
through the current study. The results from our study will
provide inputs speciﬁcally to test the logistics of the study
methodology, feasibility of doing some tests such as cord-
blood serum c-peptide, glucose testing in infants and
understanding recruitment issues in addition to mobility
of pregnant women and determinants of following them
up successfully and viability of following pregnant women
in a diverse background.
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